US Patent Issued to LENTIGEN TECHNOLOGY on July 29 for "Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy" (Maryland, Washington Inventors)

ALEXANDRIA, Va., July 30 -- United States Patent no. 12,371,490, issued on July 29, was assigned to LENTIGEN TECHNOLOGY INC. (Gaithersburg, Md.).

"Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy" was invented by Dina Schneider (Potomac, Md.), Rimas J. Orentas (Seattle), Boro Dropulic (Ellicott City, Md.) and Peirong Hu (Ijamsville, Md.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating...